Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Are Egalet Corp (EGLT)’s Chances Come PDUFA?

Egalet Corp (NASDAQ:EGLT) had a pretty tough first couple of quarters, but the third quarter of 2016 was good to the company as sentiment shifted ahead of a major potential catalyst. The FDA accepted the company’s new drug application (NDA) for its extended release morphine product, Arymo ER, back in February, and set a PDUFA of October 14, 2016. An advisory panel has already voted overwhelmingly in favor of the drug’s approval, and with a large potential market, there’s plenty of upside potential on the stock if the agency gives its drug the nod.

Here’s what’s important ahead of decision day.

As mentioned, the drug is called Arymo ER, and it is designed to target abuse deterrent pain relief in chronic pain patients. Opioid abuse is a massive problem in the US, and a large number of companies (at both ends of the spectrum) are working to try and bring various products to market to fill the unmet need.

people, person, lab, nuclear, hydrogen, concept, chemistry, technicians, researching, formula, chemists, biotechnology, researchers, discovery, weapon, samples,

Syda Productions/

Egalet Corp (NASDAQ:EGLT)’s approach isn’t particularly elegant, but it’s nice and simple – the company has basically just made the tablets very hard, so they are difficult to crush, and when added to water, they turn into a sort of sticky gel, which is difficult to inject. That’s about the long and short of it. Patients can’t break it down for preparation as part of any of the most common methods (or at least would find it very difficult to) so Egalet Corp (NASDAQ:EGLT) believes it deserves abuse deterrent labeling.

Follow Zyla Life Sciences (NASDAQ:ZCOR)
Trade (NASDAQ:ZCOR) Now!

One thing’s worth mentioning here.

In the abuse deterrent space, labeling is everything. Most of these drugs will have no problem getting approved – morphine is an established drug, and so long as the company doing the investigating can prove the pharmacokinetic profile, there’s no issue. Morphine is cheap, however, and available generically. There’s no value in a company bringing a new drug to an already flooded market, unless it’s got a USP.

Abuse deterrence is that USP.

In light of this, the fact that the advisory panel voted in favor of approval (18-1, for those interested) is not that much of a surprise, and not really indicative of success come PDUFA (again, success here is defined by labeling approval, not the drug’s approval). There were three other questions on the briefing document offered to the panel. These were:

  1. If approved, ARYMO ER should be labeled as an abuse-deterrent product by the oral route of abuse.
  2. If approved, ARYMO ER should be labeled as an abuse-deterrent product by the nasal route of abuse.
  3. If approved, ARYMO ER should be labeled as an abuse-deterrent product by the intravenous route of abuse.

The panel voted as below (in favor of vs against):

  1. 16 to 3
  2. 18 to 1
  3. 18 to 1

So, the nasal and intravenous route looks strong for an approval on that labeling. The crushing, not so strong. That’s a bit of a downside, because crushing is sort of the holy grail of this space, but it still looks pretty strong.

There is an addendum to the labeling, that will likely translate to a slightly weakened position – the panel has suggested that any approved label should reflect the fact that the drug can reduce the potential for abuse by way of the three above mentioned methods, but not eliminate it.

So that’s what we know – what’s the takeaway on this one?

The drug looks like it is going to get approved, and more importantly, it looks as though the agency is going to validate it with an abuse deterrent label. Beyond that, marketing is going to be key, and this is something the company has fallen bit short on in its other products. Cash is pretty strong, however (a little over $35 million at last count), so dilution risk is low at this stage.

Note: This article is written by Mark Collins and was originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.